Sargramostim (GM-CSF) ALS Trial

Overview

Sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor, GM-CSF, marketed as Leukine®) was evaluated in a Phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS). The rationale stemmed from the hypothesis that immunomodulation, particularly targeting the innate immune system, might provide neuroprotective benefits in ALS[@gmcsf2007].

GM-CSF is a cytokine that stimulates the production and differentiation of white blood cells, particularly granulocytes and macrophages. Beyond its well-known hematopoietic effects, GM-CSF has been shown to have immunomodulatory properties in the central nervous system, where it can influence microglial function and potentially promote neuroprotection[@engelen2002].

Trial Details

• NCT Number: NCT00035862
• Phase: Phase 2
• Status: Completed (Results published)
• Sponsor: National Institutes of Health (NIH)
• Drug: Sargramostim (Leukine®)
• Dosage: 5-7 μg/kg subcutaneously daily
• Patient Population: Adults with definite or probable ALS (El Escorial criteria)
• Duration: 8 months (29 weeks)
• Enrollment: 40 patients (randomized 2:1 active:placebo)

Background and Rationale

Role of Neuroinflammation in ALS

Overview

Sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor, GM-CSF, marketed as Leukine®) was evaluated in a Phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS). The rationale stemmed from the hypothesis that immunomodulation, particularly targeting the innate immune system, might provide neuroprotective benefits in ALS[@gmcsf2007].

GM-CSF is a cytokine that stimulates the production and differentiation of white blood cells, particularly granulocytes and macrophages. Beyond its well-known hematopoietic effects, GM-CSF has been shown to have immunomodulatory properties in the central nervous system, where it can influence microglial function and potentially promote neuroprotection[@engelen2002].

Trial Details

• NCT Number: NCT00035862
• Phase: Phase 2
• Status: Completed (Results published)
• Sponsor: National Institutes of Health (NIH)
• Drug: Sargramostim (Leukine®)
• Dosage: 5-7 μg/kg subcutaneously daily
• Patient Population: Adults with definite or probable ALS (El Escorial criteria)
• Duration: 8 months (29 weeks)
• Enrollment: 40 patients (randomized 2:1 active:placebo)

Background and Rationale

Role of Neuroinflammation in ALS

ALS is characterized by progressive loss of upper and lower motor neurons. Post-mortem studies consistently reveal extensive neuroinflammation in the spinal cord and motor cortex of ALS patients, with activated microglia surrounding degenerating motor neurons. This neuroinflammation is thought to contribute to disease progression through several mechanisms:

• Pro-inflammatory Cytokines: Elevated TNF-α, IL-1β, and IL-6 in ALS spinal cord
• Microglial Activation:Chronically activated microglia producing neurotoxic mediators
• Immune Cell Infiltration: Peripheral immune cells infiltrating the CNS
• Oxidative Stress: Inflammation-driven oxidative damage to motor neurons

GM-CSF as Immunomodulator

The rationale for using GM-CSF in ALS was based on its dual immunomodulatory properties:

Mechanism of Action

GM-CSF exerts immunomodulatory effects through multiple pathways:

Immune Cell Modulation

• Microglial Activation: Modulates microglial phenotype and function from pro-inflammatory (M1) to neuroprotective (M2) state
• Monocyte Function: Enhances monocyte/macrophage activity and phagocytic capacity
• Dendritic Cells: Affects antigen-presenting cell function and immune surveillance

Neuroprotective Effects

• Neuroinflammation Reduction: May shift microglia toward protective phenotype, reducing production of neurotoxic inflammatory mediators
• Trophic Factor Production: May increase neurotrophic factor release from immune cells (e.g., BDNF, GDNF)
• Immune Surveillance: Enhances immune cell surveillance in CNS, potentially clearing debris and toxic proteins

Molecular Mechanisms

• JAK/STAT Signaling: GM-CSF receptor activates JAK/STAT signaling pathways in target cells
• Cytokine Modulation: Alters balance of pro-inflammatory/anti-inflammatory cytokines
• Cell Survival: Promotes neuronal survival through PI3K/Akt and MAPK pathways

Trial Design

The clinical trial employed a rigorous design:

Inclusion Criteria

• Age 21-80 years
• Definite or probable ALS by El Escorial criteria
• Disease duration ≤24 months
• FVC ≥60% predicted
• No concomitant riluzole or regular immunosuppressants

Results

Key findings from the trial:

Safety Profile

• Generally Well-Tolerated: Demonstrated acceptable tolerability in ALS population
• Bone Pain: Most common adverse event, manageable with analgesics
• Leukocytosis: Expected white blood cell elevation
• No Serious Infections: Despite immune stimulation[@cudkowicz2007]

Primary Endpoint

• Did Not Meet Statistical Significance: No significant difference in ALSFRS-R decline rate between treatment and placebo arms
• Trend Toward Benefit: Numerical improvement in slope of decline favoring treatment

Secondary Endpoints

• Pulmonary Function: No significant difference in FVC decline
• Biomarkers: Evidence of target engagement (increased circulating monocytes)
• Post-hoc Analyses: Some benefit observed in specific subgroups

Exploratory Findings

• Immunomodulation: Confirmed target engagement through increased monocytes
• Subgroup Analysis: Suggestion of benefit in patients with shorter disease duration
• Biomarker Changes: Correlation between immune markers and clinical outcomes

Clinical Significance

The GM-CSF trial provides important insights for ALS drug development:

Immunomodulation Target

• Innate Immunity Focus: Validates targeting innate immune system in ALS
• Microglia Central Role: Highlights critical role of microglia in neurodegeneration
• Timing Considerations: Suggests potential benefit of earlier intervention

Biomarker Development

• Target Engagement: Immune markers can serve as biomarkers for drug activity
• Peripheral Correlates: Peripheral immune changes may reflect CNS effects
• Patient Selection: Biomarker-guided patient selection for future trials

Future Directions

• Combination Approaches: Potential for combination with other neuroprotective agents
• Dose Optimization: Exploring different dosing regimens
• Subgroup Enrichment: Focusing on patients most likely to benefit

Comparison to Other Immunomodulatory Approaches

The GM-CSF trial joins a series of immunomodulatory approaches in ALS:

| Agent | Target | Outcome |
|-------|--------|---------|
| Minocycline | Microglia | Negative (Phase 3) |
| Cyclophosphamide | T-cells | Mixed results |
| Lithium | Multiple | Negative |
| GM-CSF | Innate immunity | No significant benefit |
| Anti-STAT3 | JAK/STAT | Ongoing |

This suggests that simple immunomodulation may be insufficient; combination approaches or more targeted mechanisms may be needed.

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Microglia](/cell-types/microglia)
• [Neuroinflammation in ALS](/mechanisms/neuroinflammation-als)
• [Immunomodulatory Therapies](/clinical-trials/drug-pipeline)
• [Trophic Factors](/mechanisms/neurotrophic-factors)
• [GM-CSF Signaling](/proteins/csf2ra)

External Links

• [ClinicalTrials.gov NCT00035862](https://clinicaltrials.gov/study/NCT00035862)
• [PubMed PMID:17235047](https://pubmed.ncbi.nlm.nih.gov/17235047/)
• [Leukine Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103000s019lbl.pdf)

References

Pathway Diagram

The following diagram shows key molecular relationships for Sargramostim (GM-CSF) ALS Trial based on knowledge graph edges:

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: G3BP1
• [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
• [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
• [Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TARDBP
• [Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
• [Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: TARDBP
• [RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: G3BP1
• [Axonal RNA Transport Reconstitution](/hypothesis/h-8196b893) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: HNRNPA2B1

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Sargramostim (GM-CSF) ALS Trial discovered through SciDEX knowledge graph analysis: